ENTERPRISE AI ANALYSIS
Vitamin D in the prevention of left ventricular remodelling after an acute myocardial infarction: a randomized clinical trial
This randomized clinical trial investigated the effect of calcifediol on left ventricular remodelling and cardiac biomarkers in 93 patients with anterior ST-segment elevation myocardial infarction (STEMI) over 12 months. Despite a significant increase in calcidiol levels within the intervention group, the study found no significant differences in the primary endpoint of left ventricular remodelling (26.2% vs 21.4%; p=0.824) or any secondary endpoints related to cardiac function and inflammation biomarkers. Subgroup analyses, including patients with low calcidiol or reduced ejection fraction, yielded consistent negative results, indicating that calcifediol does not improve left ventricular remodelling or affect heart failure and inflammation biomarkers following STEMI.
Executive Impact: Key Findings at a Glance
This trial sheds light on a common intervention's effectiveness post-MI, offering critical data for clinical practice and future research directions.
0
Total Patients Analyzed
0%
Remodelling Incidence (Calcifediol Group)
p<0
Calcidiol Level Increase Significance
0
Study Duration (Months)
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
This section presents the core findings related to the trial's primary and secondary endpoints, highlighting the observed effects of calcifediol supplementation post-myocardial infarction.
Primary Endpoint: LV Remodelling Incidence
26.2% of patients in the Calcifediol group experienced LV remodelling (vs 21.4% in placebo, p=0.824).The primary endpoint, defined as a 15% increase in left ventricular end-diastolic volume, showed no significant difference between the calcifediol and placebo groups, indicating calcifediol did not prevent remodelling.
| Feature | Calcifediol Group | Placebo Group | Significance (p-value) |
|---|---|---|---|
| Calcidiol Increase (ng/mL) | 20.0 [8.4, 36.5] | 2.0 [-0.3, 4.5] | <0.001 |
| Key Finding | A significant increase in plasma calcidiol levels was observed in the intervention group, confirming the efficacy of calcifediol supplementation, yet this did not translate to clinical benefit. | ||
Study Outcome Progression
Patients with anterior STEMI randomized to calcifediol or placebo
→
Calcifediol levels significantly increased in treatment group
→
No difference in LV remodelling between groups (primary endpoint)
→
No effect on cardiac biomarkers or secondary MRI parameters
→
Conclusion: Calcifediol does not improve LV remodelling post-STEMI
Subgroup Analyses Summary
The study performed prespecified sensitivity analyses to evaluate the effect of calcifediol in various patient subgroups. Similar results were observed in patients with baseline FGF23 above the median, in those with calcidiol < 30 ng/ml, and in the subgroup with ejection fraction ≤ 40%. This indicates a consistent lack of benefit across different baseline patient characteristics, reinforcing the overall negative finding regarding calcifediol's impact on LV remodelling and cardiac biomarkers following STEMI.
Advanced ROI Calculator: Optimize Your AI Investment
Estimate the potential efficiency gains and cost savings for your enterprise by implementing tailored AI solutions, leveraging insights from cutting-edge research.
Annual Cost Savings
$0
Annual Hours Reclaimed
0
AI Implementation Roadmap
A structured approach to integrating AI into your enterprise, ensuring maximum benefit and minimal disruption.
Phase 01: Discovery & Strategy
Conduct a comprehensive audit of existing workflows and identify high-impact AI opportunities. Define clear objectives and a tailored strategy.
Phase 02: Solution Design & Prototyping
Develop custom AI models and system architecture. Create prototypes to test feasibility and refine user experience.
Phase 03: Development & Integration
Build and integrate AI solutions into your existing enterprise systems, ensuring seamless data flow and operational compatibility.
Phase 04: Deployment & Optimization
Roll out the AI solution, monitor performance, and continuously optimize algorithms for peak efficiency and measurable ROI.
Ready to Transform Your Enterprise with AI?
Let's discuss how AI-driven insights can redefine efficiency and innovation within your organization. Book a free consultation today.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat